Corresponding Author: Douglas K. Owens, MD, MS, Stanford University, 616 Serra St, Encina Hall, Room C336, Stanford, CA 94305-6019 (chair@uspstf.net).
The US Preventive Services Task Force (USPSTF) members: Douglas K. Owens, MD, MS; Karina W. Davidson, PhD, MASc; Alex H. Krist, MD, MPH; Michael J. Barry, MD; Michael Cabana, MD, MA, MPH; Aaron B. Caughey, MD, PhD; Susan J. Curry, PhD; Chyke A. Doubeni, MD, MPH; John W. Epling Jr, MD, MSEd; Martha Kubik, PhD, RN; C. Seth Landefeld, MD; Carol M. Mangione, MD, MSPH; Lori Pbert, PhD; Michael Silverstein, MD, MPH; Melissa A. Simon, MD, MPH; Chien-Wen Tseng, MD, MPH, MSEE; John B. Wong, MD.
Affiliations of The US Preventive Services Task Force (USPSTF) members: Veterans Affairs Palo Alto Health Care System, Palo Alto, California (Owens); Stanford University, Stanford, California (Owens); Feinstein Institute for Medical Research at Northwell Health, Manhasset, New York (Davidson); Fairfax Family Practice Residency, Fairfax, Virginia (Krist); Virginia Commonwealth University, Richmond (Krist); Harvard Medical School, Boston, Massachusetts (Barry); University of California, San Francisco (Cabana); Oregon Health & Science University, Portland (Caughey); University of Iowa, Iowa City (Curry); University of Pennsylvania, Philadelphia (Doubeni); Virginia Tech Carilion School of Medicine, Roanoke (Epling); Temple University, Philadelphia, Pennsylvania (Kubik); University of Alabama at Birmingham (Landefeld); University of California, Los Angeles (Mangione); University of Massachusetts Medical School, Worcester (Pbert); Boston University, Boston, Massachusetts (Silverstein); Northwestern University, Evanston, Illinois (Simon); University of Hawaii, Honolulu (Tseng); Pacific Health Research and Education Institute, Honolulu, Hawaii (Tseng); Tufts University, Medford, Massachusetts (Wong).
Accepted for Publication: April 25, 2019.
Author Contributions: Dr Owens had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The USPSTF members contributed equally to the recommendation statement.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Authors followed the policy regarding conflicts of interest described at https://www.uspreventiveservicestaskforce.org/Page/Name/conflict-of-interest-disclosures. All members of the USPSTF receive travel reimbursement and an honorarium for participating in USPSTF meetings.
Funding/Support: The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.
Role of the Funder/Sponsor: AHRQ staff assisted in the following: development and review of the research plan, commission of the systematic evidence review from an Evidence-based Practice Center, coordination of expert review and public comment of the draft evidence report and draft recommendation statement, and the writing and preparation of the final recommendation statement and its submission for publication. AHRQ staff had no role in the approval of the final recommendation statement or the decision to submit for publication.
Disclaimer: Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of AHRQ or the US Department of Health and Human Services.
Additional Contributions: We thank Howard Tracer, MD (AHRQ), who contributed to the writing of the manuscript, and Lisa Nicolella, MA (AHRQ), who assisted with coordination and editing.
7.Bavinton
BR, Pinto
AN, Phanuphak
N,
et al; Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study.
Lancet HIV. 2018;5(8):e438-e447. doi:
10.1016/S2352-3018(18)30132-2PubMedGoogle ScholarCrossref 8.Rodger
AJ, Cambiano
V, Bruun
T,
et al; PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy.
JAMA. 2016;316(2):171-181. doi:
10.1001/jama.2016.5148PubMedGoogle ScholarCrossref 9.Rodger
AJ, Cambiano
V, Bruun
T,
et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study [published online May 2, 2019].
Lancet. doi:
10.1016/S0140-6736(19)30418-0Google Scholar 11.Mathers
BM, Degenhardt
L, Phillips
B,
et al; 2007 Reference Group to the UN on HIV and Injecting Drug Use. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review.
Lancet. 2008;372(9651):1733-1745. doi:
10.1016/S0140-6736(08)61311-2PubMedGoogle ScholarCrossref 14.Mugo
NR, Heffron
R, Donnell
D,
et al; Partners in Prevention HSV/HIV Transmission Study Team. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples.
AIDS. 2011;25(15):1887-1895. doi:
10.1097/QAD.0b013e32834a9338PubMedGoogle ScholarCrossref 17.LeFevre
ML; US Preventive Services Task Force. Behavioral counseling interventions to prevent sexually transmitted infections: U.S. Preventive Services Task Force recommendation statement.
Ann Intern Med. 2014;161(12):894-901. doi:
10.7326/M14-1965PubMedGoogle ScholarCrossref 25.Grohskopf
LA, Chillag
KL, Gvetadze
R,
et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.
J Acquir Immune Defic Syndr. 2013;64(1):79-86. doi:
10.1097/QAI.0b013e31828ece33PubMedGoogle ScholarCrossref 28.Bush
S, Magnuson
D, Rawlings
MK,
et al. ASM/ICAAC: racial characteristics of FTC/TDF for pre-exposure prophylaxis (PrEP) users in the US. National AIDS Treatment Advocacy Project website.
http://www.natap.org/2016/HIV/062216_02.htm. 2016. Accessed April 16, 2019.
29.Smith
DK, Van Handel
M, Wolitski
RJ,
et al. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States, 2015.
MMWR Morb Mortal Wkly Rep. 2015;64(46):1291-1295. doi:
10.15585/mmwr.mm6446a4PubMedGoogle ScholarCrossref 31.Chou
R, Evans
C, Hoverman
A,
et al. Pre-Exposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review for the U.S. Preventive Services Task Force: Evidence Synthesis No. 178. Rockville, MD: Agency for Healthcare Research and Quality; 2018. AHRQ publication 18-05247-EF-1.
32.Chou
R, Evans
C, Hoverman
A,
et al. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force [published June 11, 2019].
JAMA. doi:
10.1001/jama.2019.2591Google Scholar 33.Beymer
MR, Weiss
RE, Sugar
CA,
et al. Are Centers for Disease Control and Prevention guidelines for preexposure prophylaxis specific enough? formulation of a personalized HIV risk score for pre-exposure prophylaxis initiation.
Sex Transm Dis. 2017;44(1):48-56. doi:
10.1097/OLQ.0000000000000535PubMedGoogle ScholarCrossref 34.Hoenigl
M, Weibel
N, Mehta
SR,
et al. Development and validation of the San Diego Early Test Score to predict acute and early HIV infection risk in men who have sex with men.
Clin Infect Dis. 2015;61(3):468-475. doi:
10.1093/cid/civ335PubMedGoogle ScholarCrossref 36.Smith
DK, Pals
SL, Herbst
JH, Shinde
S, Carey
JW. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States.
J Acquir Immune Defic Syndr. 2012;60(4):421-427. doi:
10.1097/QAI.0b013e318256b2f6PubMedGoogle ScholarCrossref 37.Jones
J, Hoenigl
M, Siegler
AJ, Sullivan
PS, Little
S, Rosenberg
E. Assessing the performance of 3 human immunodeficiency virus incidence risk scores in a cohort of black and white men who have sex with men in the South.
Sex Transm Dis. 2017;44(5):297-302. doi:
10.1097/OLQ.0000000000000596PubMedGoogle ScholarCrossref 38.Lancki
N, Almirol
E, Alon
L, McNulty
M, Schneider
JA. Preexposure prophylaxis guidelines have low sensitivity for identifying seroconverters in a sample of young black MSM in Chicago.
AIDS. 2018;32(3):383-392.
PubMedGoogle Scholar 42.Kibengo
FM, Ruzagira
E, Katende
D,
et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.
PLoS One. 2013;8(9):e74314. doi:
10.1371/journal.pone.0074314PubMedGoogle ScholarCrossref 45.Choopanya
K, Martin
M, Suntharasamai
P,
et al; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet. 2013;381(9883):2083-2090. doi:
10.1016/S0140-6736(13)61127-7PubMedGoogle ScholarCrossref 50.McCormack
S, Dunn
DT, Desai
M,
et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
Lancet. 2016;387(10013):53-60. doi:
10.1016/S0140-6736(15)00056-2PubMedGoogle ScholarCrossref 51.Cottrell
ML, Yang
KH, Prince
HM,
et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine.
J Infect Dis. 2016;214(1):55-64. doi:
10.1093/infdis/jiw077PubMedGoogle ScholarCrossref 55.Mandala
J, Nanda
K, Wang
M,
et al. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
BMC Pharmacol Toxicol. 2014;15:77. doi:
10.1186/2050-6511-15-77PubMedGoogle ScholarCrossref 56.Martin
M, Vanichseni
S, Suntharasamai
P,
et al; Bangkok Tenofovir Study Group. Renal function of participants in the Bangkok tenofovir study—Thailand, 2005-2012.
Clin Infect Dis. 2014;59(5):716-724. doi:
10.1093/cid/ciu355PubMedGoogle ScholarCrossref 58.Mugwanya
KK, Wyatt
C, Celum
C,
et al; Partners PrEP Study Team. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
JAMA Intern Med. 2015;175(2):246-254. doi:
10.1001/jamainternmed.2014.6786PubMedGoogle ScholarCrossref 60.Mulligan
K, Glidden
DV, Anderson
PL,
et al; Preexposure Prophylaxis Initiative Study Team. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind placebo-controlled trial.
Clin Infect Dis. 2015;61(4):572-580. doi:
10.1093/cid/civ324PubMedGoogle ScholarCrossref 62.Mugo
NR, Hong
T, Celum
C,
et al; Partners PrEP Study Team. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
JAMA. 2014;312(4):362-371. doi:
10.1001/jama.2014.8735PubMedGoogle ScholarCrossref 65.Connor
EM, Sperling
RS, Gelber
R,
et al; Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment.
N Engl J Med. 1994;331(18):1173-1180. doi:
10.1056/NEJM199411033311801PubMedGoogle ScholarCrossref 66.Cardo
DM, Culver
DH, Ciesielski
CA,
et al; Centers for Disease Control and Prevention Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure.
N Engl J Med. 1997;337(21):1485-1490. doi:
10.1056/NEJM199711203372101PubMedGoogle ScholarCrossref 69.Traeger
MW, Schroeder
SE, Wright
EJ,
et al. Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis.
Clin Infect Dis. 2018;67(5):676-686. doi:
10.1093/cid/ciy182PubMedGoogle ScholarCrossref 71.World Health Organization (WHO). Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd ed. WHO website.
https://www.who.int/hiv/pub/arv/arv-2016/en/. Published June 2016. Accessed April 16, 2019.